Compare GNL & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNL | AGIO |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | 56 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | N/A | 2013 |
| Metric | GNL | AGIO |
|---|---|---|
| Price | $9.53 | $24.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $9.67 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | ★ 8.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $76.75 |
| Revenue Next Year | $1.95 | $170.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.77 | $22.24 |
| 52 Week High | $10.04 | $46.00 |
| Indicator | GNL | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 31.14 |
| Support Level | $9.17 | $24.16 |
| Resistance Level | $9.75 | $29.69 |
| Average True Range (ATR) | 0.17 | 1.16 |
| MACD | -0.01 | -1.11 |
| Stochastic Oscillator | 46.34 | 4.00 |
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operation, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution, Retail, and Office. The company derives maximum revenue from the Industrial and Distribution segment. The company geographically operates in the United States, the United Kingdom, Canada, and Europe.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.